The New Republic on MSN4hOpinion
What to Expect From Trump’s Next Term: More E. Coli and Fewer Vaccines
Virus monitoring, the budgets to investigate E. coli outbreaks, and much, much more could be on the chopping block.
What is oral phynylephrine and why does the FDA want to remove it from cold medicine?
Oral phenylephrine is used in over-the-counter products like Sudafed and Dayquil to help temporarily relieve the common ...
Robert F. Kennedy Jr.’s Views Now Matter for the Nation. Here’s How He Could Influence Food and Drug Policy
Robert F. Kennedy Jr is known as a persistent critic of vaccine safety and is a longtime antagonist of the Food and Drug ...
Verywell Health on MSN2d
GLP-1 Drug Shortage Is Over. Why Might These Drugs Soon Be Costlier and Harder to Access?
The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...
Why compounders and telehealth providers are undeterred by the potential end of the weight-loss drug shortage
Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...
Fast Company9mon
food and drug administration
The Food and Drug Administration could now revoke over-the-counter designations for phenylephrine, an active ingredient in Benadryl and Sudafed. Pfizer’s COVID-19 pill: Here’s the latest on ...
Food, fluoride and funding: How a new Trump term might affect health in California
From family planning to hospital bills, the new Trump administration has the potential to affect a wide range of policies in ...
National Catholic Register21d
3 States Pick Up Abortion-Pill Lawsuit Against Food and Drug Administration
Three states have picked up a lawsuit previously dismissed by the U.S. Supreme Court earlier this year against the Food and Drug Administration (FDA) over its removal of safety restrictions on ...
Business Wire1mon
U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant
BERLIN--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for the investigational compound ...
Business Wire1mon
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
to the U.S. Food and Drug Administration (FDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is ...